文献速递肝病

低质量肌肉量而非正常质量肌肉量决定经活检证实的非酒精性脂肪性肝病纤维化进展

Low-quality muscle mass rather than normal-quality muscle mass determines fibrosis progression in biopsy-proven NAFLD.
PubMed 文献 · Aliment Pharmacol Ther · 2023-05-29

本研究纳入292例经活检证实的非酒精性脂肪性肝病(NAFLD)患者,基线时行腹部CT肌肉质量图评估骨骼肌面积并随访振动控制瞬时弹性成像至少1年,中位随访41个月。结果显示,低衰减肌肉面积(LAMA)的骨骼肌指数(SMI)四分位数升高独立增加纤维化进展风险(每四分位HR 1.41,95%CI 1.04-1.91),最高四分位较低低四分位风险增加3.25倍(95%CI 1.18-8.90);正常衰减肌肉面积(NAMA)的SMI四分位数与纤维化进展风险无关。结论认为,低质量肌肉量增加而非正常质量肌肉量减少可预测NAFLD患者纤维化进展。

要点

  • 低衰减肌肉面积骨骼肌指数(SMILAMA)每升高一个四分位,纤维化进展风险HR为1.41(95%CI 1.04-1.91)。
  • SMILAMA最高四分位较低最低四分位,纤维化进展风险增加3.25倍(95%CI 1.18-8.90)。
  • 正常衰减肌肉面积骨骼肌指数(SMINAMA)四分位数与纤维化进展风险无关。

核心结论

  • 经CT肌肉质量图评估,低质量肌肉量增加而非正常质量肌肉量减少可预测经活检证实的非酒精性脂肪性肝病(NAFLD)患者的纤维化进展。

研究设计与样本

  • 选自经活检证实的NAFLD患者共292例,均于基线后至少1年接受系列振动控制瞬时弹性成像评估。
  • 于第三腰椎水平腹部计算机断层扫描(CT)上测定骨骼肌面积(SMA),并利用肌肉质量图分为正常衰减肌肉面积(NAMA)、低衰减肌肉面积(LAMA)和肌间脂肪组织(IMAT)。
  • 将上述SMA按身高平方归一化获得骨骼肌指数(SMI)。

主要发现

  • 基线时,随组织学纤维化分期增加,SMINAMA下降(趋势p=0.014)且SMILAMA升高(趋势p<0.001),但经年龄、性别和肥胖调整后上述趋势不显著。
  • 中位随访41个月期间,292例中48例检测到纤维化进展。
  • SMILAMA四分位数升高以剂量依赖方式独立增加纤维化进展风险(每四分位风险比[HR]1.41;95%置信区间[CI]1.04-1.91)。
  • SMILAMA最高四分位较低最低四分位,纤维化进展风险增加3.25倍(95%CI 1.18-8.90)。
  • SMINAMA四分位数与纤维化进展风险无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Sarcopaenia is associated with advanced nonalcoholic fatty liver disease (NAFLD). However, the impact of the muscle mass categorised by muscle quality on fibrosis progression remains unclear. METHODS: A total of 292 patients with biopsy-proven NAFLD who underwent serial vibration-controlled transient elastography assessments at least 1 year from baseline were selected. The skeletal muscle area (SMA) was determined on abdominal computed tomography (CT) at the third lumbar vertebra level and categorised to normal-attenuation muscle area (NAMA), low-attenuation muscle area (LAMA) and intermuscular adipose tissue (IMAT) using a muscle quality map. These SMAs were normalised by the height squared to obtain the skeletal muscle index (SMI). RESULTS: At baseline, as the histological fibrosis stage increased, SMINAMA decreased and SMILAMA increased (p for trend = 0.014 and p for trend <0.001, respectively), which was not significant after adjustment for age, sex and obesity. During a median follow-up of 41 months, fibrosis progression was detected in 48 out of 292 patients, and higher SMILAMA quartiles independently increased the risk of fibrosis progression in a dose-dependent manner (hazard ratio [HR] per quartile: 1.41; 95% confidence interval [CI], 1.04-1.91). The highest quartile of SMILAMA increased the risk of fibrosis progression by 3.25 times compared to the lowest quartile of SMILAMA (95% CI, 1.18-8.90). SMINAMA quartiles were not associated with the risk of fibrosis progression. CONCLUSION: Increased low-quality muscle mass, but not decreased normal-quality muscle mass, as assessed by a muscle quality map in CT, predicts fibrosis progression in patients with NAFLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lee YK, Koo BK, Joo SK, et al. Low-quality muscle mass rather than normal-quality muscle mass determines fibrosis progression in biopsy-proven NAFLD. Aliment Pharmacol Ther. 2023. PMID: 37248793. doi:10.1111/apt.17601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。